Adaptive partial drug approval: A health policy proposal

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Charles Manski of Northwestern argues that the drug approval process should be more continuous, so that patients can have access to beneficial drugs earlier and at the same time there are incentives for longer term studies than the current system produces, which could limit problems like those caused by Vioxx.

Original languageEnglish (US)
Article numberA9
JournalEconomists' Voice
Issue number4
StatePublished - 2009


  • Clinical trials
  • Diversification
  • Food and Drug Administration

ASJC Scopus subject areas

  • Business, Management and Accounting(all)
  • Economics, Econometrics and Finance(all)


Dive into the research topics of 'Adaptive partial drug approval: A health policy proposal'. Together they form a unique fingerprint.

Cite this